Key result
Quantitative PET and SPECT molecular imaging shows promise for CV diagnostics despite slow clinical adoption.
Why the study?
Clinical implementation of new advances in quantitative molecular imaging has been slow, despite its potential to improve precision medicine and health outcomes in cardiovascular diseases.
Advanced quantitative molecular imaging techniques like PET and SPECT could enable precision medicine in cardiovascular disease by improving early diagnosis and treatment monitoring, provided technical and standardization challenges are overcome.
May support precision CV diagnostics with PET/SPECT; leaves open routine adoption pending standardization.
Cardiovascular diseases (CVD) are the leading cause of death worldwide and have an increasing impact on society. Precision medicine, in which optimal care is identified for an individual or a group of individuals rather than for the average population, might provide significant health benefits for this patient group and decrease CVD morbidity and mortality. Molecular imaging provides the opportunity to assess biological processes in individuals in addition to anatomical context provided by other imaging modalities and could prove to be essential in the implementation of precision medicine in CVD. New developments in single-photon emission computed tomography (SPECT) and positron emission tomography (PET) systems, combined with rapid innovations in promising and specific radiopharmaceuticals, provide an impressive improvement of diagnostic accuracy and therapy evaluation. This may result in improved health outcomes in CVD patients, thereby reducing societal impact. Furthermore, recent technical advances have led to new possibilities for accurate image quantification, dynamic imaging, and quantification of radiotracer kinetics. This potentially allows for better evaluation of disease activity over time and treatment response monitoring. However, the clinical implementation of these new methods has been slow. This review describes the recent advances in molecular imaging and the clinical value of quantitative PET and SPECT in various fields in cardiovascular molecular imaging, such as atherosclerosis, myocardial perfusion and ischemia, infiltrative cardiomyopathies, systemic vascular diseases, and infectious cardiovascular diseases. Moreover, the challenges that need to be overcome to achieve clinical translation are addressed, and future directions are provided.
No takes yet. Share an insight, caveat, or question.
Tingen et al. (2023) conducted a review in Cardiovascular diseases. Quantitative cardiovascular molecular imaging (PET and SPECT) vs. Visual assessment was evaluated. Quantitative cardiovascular molecular imaging using PET and SPECT offers potential to improve diagnostic accuracy and therapy evaluation in cardiovascular diseases, though clinical implementation is slow.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: